Language

Dermatology

Dermatology - Research

We have recently partnered with Pace Dermatology to bring more accessible and innovative dermatology treatments to patients in the South Sound and Pacific Northwest. Together, patients benefit from the research expertise of the MultiCare’s Institute for Research & Innovation and the highly-skilled, passionate clinical team at Pace Dermatology. 

Dermatology studies include, but are not limited to, the following therapeutic areas:

  • Psoriasis
  • Atopic dermatitis
  • Pediatric trails coming soon

Drs. Aaron and Andrew Pace lead Pace Dermatology – with locations in Tacoma and Lakewood. They are board certified in dermatology, so patients can expect the highest level of care. 

Please click here to learn more about Pace Dermatology.

Dermatology Studies Accepting Participants

Allure AIN457 Psoriasis

Study Number: CAIN457A2323 – a multicenter, randomized, double-blind, placebo-controlled, 52-week study to demonstrate the efficacy, safety, and tolerability of subcutaneous Secukinumab injections with 2mL pre-filled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis—ALLURE.

Study Info

Principal Investigator: Andrew Pace, MD

Study Coordinator: Shannon Harris, [email protected], 253-301-6992

Regeneron Atopic Dermatitis

Study Number: Regeneron R668-AD-1607 - An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis.

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992

Adult - Biomarker Study

Study Number: MTG-002 - Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients.

Principal Investigator: Andrew Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992

Pediatric - Regeneron Atopic Dermattis

Study Number: Regeneron R668-AD01539 - A phase 2/3 study investigating the pharamcokintics, safety, efficacy of Duplimab in patients aged > 6 months to <6 years wuth severe atopic dermatitis. 

Principal Investigator: Jeffrey Jacobs, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992